The Utility of In Vitro Data in Making Accurate Predictions of Human P-Glycoprotein-Mediated Drug-Drug Interactions: A Case Study for AZD5672

2010 ◽  
Vol 39 (2) ◽  
pp. 275-282 ◽  
Author(s):  
Robert Elsby ◽  
Michael Gillen ◽  
Caroline Butters ◽  
Gemma Imisson ◽  
Pradeep Sharma ◽  
...  
Keyword(s):  
Drug Interactions ◽  
P Glycoprotein ◽  
Vitro Data ◽  
In Vitro Data

Prediction of CYP2D6 Drug Interactions from In Vitro Data: Evidence for Substrate-Dependent Inhibition

2011 ◽  
Vol 40 (1) ◽  
pp. 47-53 ◽  
Author(s):  
Brooke M. VandenBrink ◽  
Robert S. Foti ◽  
Dan A. Rock ◽  
Larry C. Wienkers ◽  
Jan L. Wahlstrom
Keyword(s):  
Drug Interactions ◽  
Dependent Inhibition ◽  
Vitro Data ◽  
In Vitro Data

scholarly journals Modeling of Rifampicin-Induced CYP3A4 Activation Dynamics for the Prediction of Clinical Drug-Drug Interactions from In Vitro Data

PLoS ONE ◽  
2013 ◽  
Vol 8 (9) ◽  
pp. e70330 ◽  
Author(s):  
Fumiyoshi Yamashita ◽  
Yukako Sasa ◽  
Shuya Yoshida ◽  
Akihiro Hisaka ◽  
Yoshiyuki Asai ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Activation Dynamics ◽  
Vitro Data ◽  
Clinical Drug ◽  
In Vitro Data

scholarly journals How well can in vitro data predict in vivo effects of chemicals? Rodent carcinogenicity as a case study

2016 ◽  
Vol 77 ◽  
pp. 54-64 ◽  
Author(s):  
Louis Anthony (Tony) Cox ◽  
Douglas A. Popken ◽  
A. Michael Kaplan ◽  
Laura M. Plunkett ◽  
Richard A. Becker
Keyword(s):  
In Vivo Effects ◽  
Vitro Data ◽  
In Vitro Data ◽  
Rodent Carcinogenicity

Challenges of Using In Vitro Data for Modeling P-Glycoprotein Efflux in the Blood-Brain Barrier

2013 ◽  
Vol 31 (1) ◽  
pp. 1-19 ◽  
Author(s):  
Noora Sjöstedt ◽  
Hanna Kortejärvi ◽  
Heidi Kidron ◽  
Kati-Sisko Vellonen ◽  
Arto Urtti ◽  
...  
Keyword(s):  
Blood Brain Barrier ◽  
Brain Barrier ◽  
P Glycoprotein ◽  
Blood Brain ◽  
Vitro Data ◽  
In Vitro Data

Prediction of In Vivo Drug-Drug Interactions from In Vitro Data

2006 ◽  
Vol 45 (10) ◽  
pp. 1035-1050 ◽  
Author(s):  
Hayley S Brown ◽  
Aleksandra Galetin ◽  
David Hallifax ◽  
J Brian Houston
Keyword(s):  
Drug Interactions ◽  
Vitro Data ◽  
In Vitro Data

scholarly journals Drug–Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes

Pharmaceutics ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 1201
Author(s):  
Florian Klomp ◽  
Christoph Wenzel ◽  
Marek Drozdzik ◽  
Stefan Oswald
Keyword(s):  
Drug Interactions ◽  
Therapeutic Index ◽  
Human Intestine ◽  
Drug Reactions ◽  
Narrow Therapeutic Index ◽  
Regulation Function ◽  
And Function ◽  
Vitro Data ◽  
In Vitro Data

Cytochrome P450 (CYP) 1A enzymes are considerably expressed in the human intestine and liver and involved in the biotransformation of about 10% of marketed drugs. Despite this doubtless clinical relevance, CYP1A1 and CYP1A2 are still somewhat underestimated in terms of unwanted side effects and drug–drug interactions of their respective substrates. In contrast to this, many frequently prescribed drugs that are subjected to extensive CYP1A-mediated metabolism show a narrow therapeutic index and serious adverse drug reactions. Consequently, those drugs are vulnerable to any kind of inhibition or induction in the expression and function of CYP1A. However, available in vitro data are not necessarily predictive for the occurrence of clinically relevant drug–drug interactions. Thus, this review aims to provide an up-to-date summary on the expression, regulation, function, and drug–drug interactions of CYP1A enzymes in humans.

Sign in / Sign up

Export Citation Format

Share Document